Rebecca Starble
Postdoctoral AssociateAbout
Research
Publications
2026
Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development
Garcia CC, Venkat A, McQuaid DC, Agabiti SS, Tong A, Mathew B, Cardone RL, Starble R, Ruiz CF, Zheng C, Sogunro A, Jacox JB, Loh KH, Kibbey RG, Krishnaswamy S, Muzumdar MD. Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development. Nature Communications 2026 DOI: 10.1038/s41467-026-69821-2.Peer-Reviewed Original ResearchThis study investigates how beta cell-derived cholecystokinin drives obesity-associated pancreatic cancer development, showing that targeting endocrine signaling could prevent tumor progression in obesity-related contexts.Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development
Garcia C, Venkat A, McQuaid D, Agabiti S, Tong A, Mathew B, Cardone R, Starble R, Ruiz C, Zheng C, Sogunro A, Jacox J, Loh K, Kibbey R, Krishnaswamy S, Muzumdar M. Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development. Nature Communications 2026 PMID: 41760660, DOI: 10.1038/s41467-026-69821-2.Peer-Reviewed Original ResearchPancreatic adenocarcinomaImmature B cellsCell-derived tumorsCell secretionCell transcriptional statesSingle-cell RNA sequencingHost metabolic statePancreatic adenocarcinoma developmentBona fide driversExperimental lineagesPeptide hormone cholecystokininTranscriptional statesB cellsCholecystokinin expressionAdenocarcinoma developmentCCK signalingSecretion of insulinHormone cholecystokininCell expressionRNA sequencingTumor formationCholecystokininPDAC developmentPDAC progressionIslet beta
2025
Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification
Starble R, Sun E, Gbyli R, Radda J, Lu J, Jensen T, Sun N, Khudaverdyan N, Zhao T, Hu B, Melnick M, Zhao S, Roper N, Wang G, Tackett A, Wang Y, Song J, Politi K, Wang S, Xiao A. Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification. Nature Structural & Molecular Biology 2025, 33: 7-19. PMID: 41131337, PMCID: PMC12819156, DOI: 10.1038/s41594-025-01685-4.Peer-Reviewed Original ResearchInter-TAD interactionsChromatin functionOncogene amplificationCopy numberChromatin regulatory functionsIncrease of H3K27acInner nuclear membraneLung adenocarcinomaExpression of tumor-promoting genesTKI resistanceCopy number gainGene copy numberAmplified lociChromatin signaturesCohesin depositionCohesin recruitmentCohesin loadingGenome stabilityTumor-promoting genesPhenotypic effectsMammalian cellsEndoplasmic reticulumDrug-naive cellsTyrosine kinase inhibitor resistanceTKI-resistant tumors